1. Home
  2. NVCR vs MGNI Comparison

NVCR vs MGNI Comparison

Compare NVCR & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • MGNI
  • Stock Information
  • Founded
  • NVCR 2000
  • MGNI 2007
  • Country
  • NVCR Jersey
  • MGNI United States
  • Employees
  • NVCR N/A
  • MGNI N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • MGNI Computer Software: Programming Data Processing
  • Sector
  • NVCR Health Care
  • MGNI Technology
  • Exchange
  • NVCR Nasdaq
  • MGNI Nasdaq
  • Market Cap
  • NVCR 1.8B
  • MGNI 1.7B
  • IPO Year
  • NVCR 2015
  • MGNI N/A
  • Fundamental
  • Price
  • NVCR $17.49
  • MGNI $12.94
  • Analyst Decision
  • NVCR Buy
  • MGNI Strong Buy
  • Analyst Count
  • NVCR 5
  • MGNI 11
  • Target Price
  • NVCR $26.60
  • MGNI $16.95
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • MGNI 1.3M
  • Earning Date
  • NVCR 10-30-2024
  • MGNI 11-07-2024
  • Dividend Yield
  • NVCR N/A
  • MGNI N/A
  • EPS Growth
  • NVCR N/A
  • MGNI N/A
  • EPS
  • NVCR N/A
  • MGNI N/A
  • Revenue
  • NVCR $549,964,000.00
  • MGNI $649,216,000.00
  • Revenue This Year
  • NVCR $16.23
  • MGNI $0.26
  • Revenue Next Year
  • NVCR $6.09
  • MGNI $10.75
  • P/E Ratio
  • NVCR N/A
  • MGNI N/A
  • Revenue Growth
  • NVCR 8.33
  • MGNI 7.50
  • 52 Week Low
  • NVCR $10.87
  • MGNI $6.46
  • 52 Week High
  • NVCR $24.74
  • MGNI $15.92
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 43.24
  • MGNI 54.59
  • Support Level
  • NVCR $15.61
  • MGNI $12.35
  • Resistance Level
  • NVCR $17.31
  • MGNI $13.11
  • Average True Range (ATR)
  • NVCR 1.29
  • MGNI 0.42
  • MACD
  • NVCR 0.05
  • MGNI 0.11
  • Stochastic Oscillator
  • NVCR 11.59
  • MGNI 63.58

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About MGNI Magnite Inc.

Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.

Share on Social Networks: